ArticleMultiple sclerosis journal - experimental, translational and clinical

A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs.

James D Bowen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.